Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Korean Health Ministry Hesitant To Punish Doctors For Accepting Pharma Rebates

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs denied a string of pharma industry expectations and local press reports that it was moving to tighten legal restrictions and punishments for doctors who accept rebates from pharmaceutical companies

You may also be interested in...



Korea's Anti-Rebate Laws Seen Sparking More Demand For MNC Products

SEOUL - Last week's passage of long-awaited "anti-rebate laws" that enable courts to punish both contributors and receivers of rebates, could trigger more demand from doctors to prescribe branded products from multinational companies, industry watchers said

Korea's Anti-Rebate Laws Seen Sparking More Demand For MNC Products

SEOUL - Last week's passage of long-awaited "anti-rebate laws" that enable courts to punish both contributors and receivers of rebates, could trigger more demand from doctors to prescribe branded products from multinational companies, industry watchers said

Leading Korean Pharma Companies Issued Fines In First Court Intervention Case Over Rebates

SEOUL - In the first court-involved case over rebates, three leading local South Korean pharma companies were issued stiff fines for "excessively unfair" business practices incurred by providing rebates to doctors and hospital

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel